Form 4: Arteris Inc. CEO Charles Janac Sells Shares Under 10b5-1 Plan, Corrects Previous Filing Error

Arteris Inc.'s CEO, Charles Janac, sold 8,432 shares of common stock at an average price of $12.3382 per share under a pre-arranged 10b5-1 trading plan and corrected a previous reporting error.

Summary

• Charles Janac, CEO of Arteris Inc., sold 8,432 shares of common stock on January 6, 2025, at a weighted average price of $12.3382 per share.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on February 27, 2024.
• The shares were sold in multiple transactions with prices ranging from $12.17 to $12.60.
• Janac also corrected a previous reporting error in Form 4 filings between December 13, 2024, and January 6, 2025, which overstated the number of shares held by the Charles and Lydia Janac Trust by 14,034 shares.
• Following the transaction, Janac directly owns 260,088 shares and indirectly owns 9,957,691 shares through Bayview Legacy, LLC, and 63,252 shares through the Charles and Lydia Janac Trust.

Sentiment

Score: 6

Explanation: The document is neutral, detailing a routine stock sale under a pre-arranged plan and a correction of a previous reporting error. There is no indication of positive or negative sentiment.

Risks

• The sale of shares by the CEO could be perceived negatively by some investors, potentially impacting the stock price.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the technology sector like ARM Holdings or Synopsys, to manage their personal finances while avoiding accusations of insider trading.
• The reporting of insider transactions via Form 4 filings is a standard regulatory requirement for all publicly traded companies in the US, ensuring transparency in the market.
• The correction of a reporting error is not uncommon and demonstrates the company's commitment to accurate financial reporting, similar to how other companies like Cadence Design Systems or Marvell Technology would handle such situations.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The correction of the reporting error should reassure stakeholders about the company's commitment to accurate financial reporting.

Key Dates

Keywords

Arteris Inc., Charles Janac, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, share transaction